Skip to main content
The AAPS Journal logoLink to The AAPS Journal
. 2006 Feb 3;8(1):E48–E54. doi: 10.1208/aapsj080106

Mechanisms of drug-induced liver injury

Michael P Holt 1, Cynthia Ju 1,
PMCID: PMC2751423  PMID: 16584133

Abstract

The idiosyncratic nature and poor prognosis of drug-induced liver injury (DILI) make this type of reaction a major safety issue during drug development, as well as the most common cause for the withdrawal of drugs from the pharmaceutical market. The key to predicting and preventing DILI is understanding the underlying mechanisms. DILI is initiated by direct hepatotoxic effects of a drug, or a reactive metabolite of a drug. Parenchymal cell injury induces activation of innate and/or adaptive immune cells, which, in turn, produce proinflammatory and tissue hepatotoxic mediators, and/or mount immune reactions against drug-associated antigens. Understanding the molecular and cellular elements associated with these pathways can help identify risk factors and may ultimately facilitate the development of strategies to predict and prevent DILI.

Keywords: Adverse drug reaction, hepatotoxicity, inflammation, innate immunity, adaptive immunity

Full Text

The Full Text of this article is available as a PDF (257.8 KB).

References

  • 1.Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954. doi: 10.7326/0003-4819-137-12-200212170-00007. [DOI] [PubMed] [Google Scholar]
  • 2.Zimmerman HJ. Drug-induced liver disease. In: Zimmerman HJ, editor. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999. pp. 427–456. [Google Scholar]
  • 3.Hunter EB, Johnston PE, Tanner G, Pinson CW, Awad JA. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation. Am J Gastroenterol. 1999;94:2299–2301. doi: 10.1111/j.1572-0241.1999.01321.x. [DOI] [PubMed] [Google Scholar]
  • 4.Anonymous. Withdrawal of medicinal products containing ebrotidine: liver toxicity.WHO Inform Exchange Syst. 1998;72:1.
  • 5.Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol. 2000;95:272–276. doi: 10.1111/j.1572-0241.2000.01707.x. [DOI] [PubMed] [Google Scholar]
  • 6.Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215–2220. doi: 10.1001/jama.287.17.2215. [DOI] [PubMed] [Google Scholar]
  • 7.Thames G. Drug-induced liver injury: what you need to know. Gastroenterol Nurs. 2004;27:31–33. doi: 10.1097/00001610-200401000-00008. [DOI] [PubMed] [Google Scholar]
  • 8.Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA. 2002;287:2273–2275. doi: 10.1001/jama.287.17.2273. [DOI] [PubMed] [Google Scholar]
  • 9.Blazka ME, Wilmer JL, Holladay SD, Wilson RE, Luster MI. Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol. 1995;133:43–52. doi: 10.1006/taap.1995.1125. [DOI] [PubMed] [Google Scholar]
  • 10.Blazka ME, Elwell MR, Holladay SD, Wilson RE, Luster MI. Histopathology of acetaminophen-induced liver changes: role of interleukin 1 alpha and tumor necrosis factor alpha. Toxicol Pathol. 1996;24:181–189. doi: 10.1177/019262339602400206. [DOI] [PubMed] [Google Scholar]
  • 11.Ishida Y, Kondo T, Ohshima T, Fujiwara H, Iwakura Y, Mukaida N. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J. 2002;16:1227–1236. doi: 10.1096/fj.02-0046com. [DOI] [PubMed] [Google Scholar]
  • 12.Bourdi M, Masubuchi Y, Reilly TP, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology. 2002;35:289–298. doi: 10.1053/jhep.2002.30956. [DOI] [PubMed] [Google Scholar]
  • 13.Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun. 2003;304:207–212. doi: 10.1016/S0006-291X(03)00572-2. [DOI] [PubMed] [Google Scholar]
  • 14.Reilly TP, Brady JN, Marchick MR, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol. 2001;14:1620–1628. doi: 10.1021/tx0155505. [DOI] [PubMed] [Google Scholar]
  • 15.Bourdi M, Tinel M, Beaune PH, Pessayre D. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol. 1994;45:1287–1295. [PubMed] [Google Scholar]
  • 16.Lecoeur S, Andre C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol. 1996;50:326–333. [PubMed] [Google Scholar]
  • 17.Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003;111:1393–1403. doi: 10.1067/mai.2003.1507. [DOI] [PubMed] [Google Scholar]
  • 18.Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003;63:732–741. doi: 10.1124/mol.63.3.732. [DOI] [PubMed] [Google Scholar]
  • 19.Satoh H, Martin BM, Schulick AH, Christ DD, Kenna JG, Pohl LR. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc Natl Acad Sci USA. 1989;86:322–326. doi: 10.1073/pnas.86.1.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC-dependent presentation of the drug sulfam ethoxazole to human alphabeta T cell clones. J Clin Invest. 1997;100:136–141. doi: 10.1172/JCI119505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Vergani D, Mieli-Vergani G, Alberti A, et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med. 1980;303:66–71. doi: 10.1056/NEJM198007103030202. [DOI] [PubMed] [Google Scholar]
  • 22.Larrey D. Drug-induced liver diseases. J Hepatol. 2000;32:77–88. doi: 10.1016/S0168-8278(00)80417-1. [DOI] [PubMed] [Google Scholar]
  • 23.Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev. 2004;36:301–312. doi: 10.1081/DMR-120034148. [DOI] [PubMed] [Google Scholar]
  • 24.Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis. 2000;4:73–96. doi: 10.1016/S1089-3261(05)70097-0. [DOI] [PubMed] [Google Scholar]
  • 25.Pessayre O, Larrey D, Biour M. Drug-induced liver injury. In: Bircher J, Benhamou J, McIntyre N, editors. Oxford Textbook of Clinical Hepatology. Oxford, England: Oxford University Press; 1999. pp. 1261–1315. [Google Scholar]
  • 26.Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–485. doi: 10.1056/NEJMra021844. [DOI] [PubMed] [Google Scholar]
  • 27.Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis, I: role of drug metabolism. J Pharmacol Exp Ther. 1973;187:185–194. [PubMed] [Google Scholar]
  • 28.Donnelly PJ, Walker RM, Racz WJ. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity. Arch Toxicol. 1994;68:110–118. doi: 10.1007/s002040050043. [DOI] [PubMed] [Google Scholar]
  • 29.Meyers LL, Beierschmitt WP, Khairallah EA, Cohen SD. Acetaminophen-induced inhibition of hepatic mitochondrial respiration in mice. Toxicol Appl Pharmacol. 1988;93:378–387. doi: 10.1016/0041-008X(88)90040-3. [DOI] [PubMed] [Google Scholar]
  • 30.Li Z, Diehl AM. Innate immunity in the liver. Curr Opin Gastroenterol. 2003;19:565–571. doi: 10.1097/00001574-200311000-00009. [DOI] [PubMed] [Google Scholar]
  • 31.Hashimoto W, Takeda K, Anzai R, et al. Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol. 1995;154:4333–4340. [PubMed] [Google Scholar]
  • 32.Tsutsui H, Matsui K, Kawada N, et al. IL-18 accounts for both TNF-alpha-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol. 1997;159:3961–3967. [PubMed] [Google Scholar]
  • 33.Rubinstein D, Roska AK, Lipsky PE. Liver sinusoidal lining cells express class II major histocompatibility antigens but are poor stimulators of fresh allogeneic T lymphocytes. J Immunol. 1986;137:1803–1810. [PubMed] [Google Scholar]
  • 34.Callery MP, Kamei T, Flye MW. Kupffer cell blockade inhibits induction of tolerance by the portal venous route. Transplantation. 1989;47:1092–1094. doi: 10.1097/00007890-198906000-00041. [DOI] [PubMed] [Google Scholar]
  • 35.Kamei T, Callery MP, Flye MW. Kupffer cell blockade prevents induction of portal venous tolerance in rat cardiac allograft transplantation. J Surg Res. 1990;48:393–396. doi: 10.1016/0022-4804(90)90001-I. [DOI] [PubMed] [Google Scholar]
  • 36.Squiers EC, Salomon DR, Pickard LL, Howard RR, Pfaff WW. Abrogation of the induction of portal venous tolerance in a cardiac transplant model resulting from Kupffer cell inhibition by gadolinium. Transplantation. 1990;50:171–173. doi: 10.1097/00007890-199007000-00036. [DOI] [PubMed] [Google Scholar]
  • 37.Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology. 2001;120:250–260. doi: 10.1053/gast.2001.20947. [DOI] [PubMed] [Google Scholar]
  • 38.Doherty DG, Norris S, Madrigal-Estebas L, et al. The human liver contains multiple populations of NK cells, T cells, and CD3+CD56+natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol. 1999;163:2314–2321. [PubMed] [Google Scholar]
  • 39.Chen H, Paul WE. Cultured NK1.1+CD4+T cells produce large amounts of IL-4 and IFN-gamma upon activation by anti-CD3 or CD1. J Immunol. 1997;159:2240–2249. [PubMed] [Google Scholar]
  • 40.Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in the human liver. Immunol Rev. 2000;174:5–20. doi: 10.1034/j.1600-0528.2002.017416.x. [DOI] [PubMed] [Google Scholar]
  • 41.Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell. 1994;76:241–251. doi: 10.1016/0092-8674(94)90332-8. [DOI] [PubMed] [Google Scholar]
  • 42.Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature. 1969;223:472–476. doi: 10.1038/223472a0. [DOI] [PubMed] [Google Scholar]
  • 43.Gorczynski RM, Chan Z, Chung S, et al. Prolongation of rat small bowel or renal allograft survival by pretransplant transfusion and/or by varying the route of allograft venous drainage. Transplantation. 1994;58:816–820. [PubMed] [Google Scholar]
  • 44.Rao VK, Burris DE, Gruel SM, Sollinger HW, Burlingham WJ. Evidence that donor spleen cells administered through the portal vein prolong the survival of cardiac allografts in rats. Transplantation. 1988;45:1145–1146. doi: 10.1097/00007890-198806000-00032. [DOI] [PubMed] [Google Scholar]
  • 45.Cantor HM, Dumont AE. Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature. 1967;215:744–745. doi: 10.1038/215744a0. [DOI] [PubMed] [Google Scholar]
  • 46.Chen Y, Ong CR, McKenna GJ, Mui AL, Smith RM, Chung SW. Induction of immune hyporesponsiveness after portal vein immunization with ovalbumin. Surgery. 2001;129:66–75. doi: 10.1067/msy.2001.109059. [DOI] [PubMed] [Google Scholar]
  • 47.Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev. 2000;174:47–62. doi: 10.1034/j.1600-0528.2002.017412.x. [DOI] [PubMed] [Google Scholar]
  • 48.Bertolino P, Heath WR, Hardy CL, Morahan G, Miller JF. Peripheral deletion of autoreactive CD8+T cells in transgenic mice expressing H-2Kb in the liver. Eur J Immunol. 1995;25:1932–1942. doi: 10.1002/eji.1830250721. [DOI] [PubMed] [Google Scholar]
  • 49.Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN. The liver eliminates T cells undergoing antigen-triggered apoptosis in vivo. Immunity. 1994;1:741–749. doi: 10.1016/S1074-7613(94)80016-2. [DOI] [PubMed] [Google Scholar]
  • 50.Klugewitz K, Blumenthal-Barby F, Schrage A, Knolle PA, Hamann A, Crispe IN. Immunomodulatory effects of the liver: deletion of activated CD4+effector cells and suppression of IFN-gamma-producing cells after intravenous protein immunization. J Immunol. 2002;169:2407–2413. doi: 10.4049/jimmunol.169.5.2407. [DOI] [PubMed] [Google Scholar]
  • 51.Knolle PA, Schmitt E, Jin S, et al. Induction of cytokine production in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells. Gastroenterology. 1999;116:1428–1440. doi: 10.1016/S0016-5085(99)70508-1. [DOI] [PubMed] [Google Scholar]
  • 52.Limmer A, Ohl J, Kurts C, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6:1348–1354. doi: 10.1038/82161. [DOI] [PubMed] [Google Scholar]
  • 53.Pillarisetty VG, Shah AB, Miller G, Bleier JI, DeMatteo RP. Liver dendritic cells are less immunogenic than spleen dendritic cells because of differences in subtype composition. J Immunol. 2004;172:1009–1017. doi: 10.4049/jimmunol.172.2.1009. [DOI] [PubMed] [Google Scholar]
  • 54.Liu ZX, Govindarajan S, Kaplowitz N. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology. 2004;127:1760–1774. doi: 10.1053/j.gastro.2004.08.053. [DOI] [PubMed] [Google Scholar]
  • 55.Laskin DL, Gardner CR, Price VF, Jollow DJ. Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. Hepatology. 1995;21:1045–1050. doi: 10.1002/hep.1840210424. [DOI] [PubMed] [Google Scholar]
  • 56.Michael SL, Punford NR, Mayeux PR, Niesman MR, Hinson JA. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology. 1999;30:186–195. doi: 10.1002/hep.510300104. [DOI] [PubMed] [Google Scholar]
  • 57.Ju C, Reilly TP, Bourdi M, et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem Res Toxicol. 2002;15:1504–1513. doi: 10.1021/tx0255976. [DOI] [PubMed] [Google Scholar]
  • 58.Lawson JA, Farhood A, Hopper RD, Bajt ML, Jaeschke H. The hepatic inflammatory response after acetaminophen overdose: role of neutrophils. Toxicol Sci. 2000;54:509–516. doi: 10.1093/toxsci/54.2.509. [DOI] [PubMed] [Google Scholar]
  • 59.Smith GS, Nadig DE, Kokoska ER, Solomon H, Tiniakos DG, Miller TA. Role of neutrophils in hepatotoxicity induced by oral acetaminophen administration in rats. J Surg Res. 1998;80:252–258. doi: 10.1006/jsre.1998.5441. [DOI] [PubMed] [Google Scholar]
  • 60.Zimmerman HJ. Drug-induced liver disease. In: Schiff E, Sorrell M, Maddrey W, editors. Schiff's Diseases of the Liver. Philadelphia, PA: Lippincott-Raven; 1999. pp. 973–1064. [Google Scholar]
  • 61.Aithal GP, Ramsay L, Daly AK, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39:1430–1440. doi: 10.1002/hep.20205. [DOI] [PubMed] [Google Scholar]

Articles from The AAPS Journal are provided here courtesy of American Association of Pharmaceutical Scientists

RESOURCES